BYSI Stock - BeyondSpring Inc.
Unlock GoAI Insights for BYSI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $1.35M | $1.35M | $180,000 |
| Gross Profit | N/A | $-302,000 | $1.35M | $1.35M | $180,000 |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-8,754,000 | $-15,081,000 | $-37,239,000 | $-66,240,000 | $-64,211,000 |
| Net Income | $-11,123,000 | $-21,026,000 | $-33,279,000 | $-64,179,000 | $-60,973,000 |
| Net Margin | N/A | N/A | -2463.3% | -4750.5% | -33873.9% |
| EPS | $-0.28 | $-0.54 | $-0.85 | $-1.64 | $-2.04 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Visit WebsiteEarnings History & Surprises
BYSIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-0.05 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.04 | — | — |
Q2 2025 | May 12, 2025 | — | $-0.06 | — | — |
Q1 2025 | Mar 27, 2025 | — | $0.08 | — | — |
Q3 2024 | Aug 9, 2024 | — | $-0.09 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.11 | — | — |
Q2 2024 | Apr 11, 2024 | — | $-0.09 | — | — |
Q1 2024 | Feb 28, 2024 | — | $-0.16 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.11 | — | — |
Q2 2023 | Apr 18, 2023 | $-0.58 | $-0.19 | +67.4% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | — | $-0.16 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-0.24 | — | — |
Q3 2022 | Sep 30, 2022 | $-0.23 | $-0.19 | +17.8% | ✓ BEAT |
Q2 2022 | Apr 14, 2022 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-0.24 | — | — |
Q4 2021 | Dec 30, 2021 | $-0.58 | $-0.47 | +19.0% | ✓ BEAT |
Q3 2021 | Sep 10, 2021 | $-0.49 | $-0.49 | 0.0% | = MET |
Q2 2021 | Jun 16, 2021 | $-0.54 | $-0.44 | +18.5% | ✓ BEAT |
Q2 2021 | Apr 30, 2021 | $-0.45 | $-0.52 | -15.6% | ✗ MISS |
Q4 2020 | Nov 17, 2020 | $-0.54 | $-0.48 | +11.1% | ✓ BEAT |
Latest News
BeyondSpring Announces Asian Subset Results From Phase 3 DUBLIN-3 Trial Of Plinabulin In EGFR Wild-Type NSCLC At ESMO Asia 2025
➖ NeutralBeyondSpring Announces New Post-Hoc Analyses From Global Phase 3 DUBLIN-3 Study, Showing Plinabulin Plus Docetaxel Provides Clinically Meaningful Benefit For Patients With EGFR WT NSQ NSCLC
📈 PositiveBeyondSpring Q3 EPS $(0.04) Up From $(0.05) YoY
📈 PositiveBeyondSpring Cash Jumps in Fiscal Q2
📈 PositiveFrequently Asked Questions about BYSI
What is BYSI's current stock price?
What is the analyst price target for BYSI?
What sector is BeyondSpring Inc. in?
What is BYSI's market cap?
Does BYSI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BYSI for comparison